Genotype-dependent response to desmopressin in hemophilia A and proposal of a predictive response score

去氨加压素 医学 内科学 胃肠病学 基础(医学) 凝血病 胰岛素
作者
Benoît Guillet,Maxime Pawlowski,Pierre Boisseau,Yohann Repessé,Philippe Beurrier,Sophie Bayart,Xavier Delavenne,Marc Trossaërt,Peter J. Lenting
出处
期刊:Thrombosis and Haemostasis [Georg Thieme Verlag KG]
标识
DOI:10.1055/a-2329-3375
摘要

Background Desmopressin (DDAVP) is used in patients with moderate/mild hemophilia A (PWMHs) to increase their factor VIII (FVIII) level and, if possible, normalize it. However, its effectiveness varies between individuals. The GIDEMHA study aims to investigate the influence of F8 gene variants. Material and Methods The study collected the trajectory of FVIII levels from therapeutic intravenous DDAVP tests in four French hemophilia treatment centers. A pharmacological analysis was performed associated with efficacy scores according to F8 variants: absolute and relative responses, as well as new scores: absolute duration (based on duration with FVIII ≥ 0.50 IU.mL−1) and relative duration (based on half-life). Results From enrolled 439 PWMHs, 327 had a hot-spot F8 variant (with ≥5 PWMHs). For these, the median (min–max) basal and peak FVIII were 0.20 (0.02–0.040) and 0.74 (0.14–2.18) IU.mL−1 respectively, with FVIII recovery being 3.80 IU.ml−1 (1.15–14.75). The median FVIII half-life was 3.9 hours (0.7–15.9 hours). FVIII was normalized (≥0.50 IU.mL−1) in 224/327 PWMHs (69%) and the median time with normalized FVIII was 3.9 hours (0.0–54.1 hours). Following the response profiles to DDAVP defined by the four efficacy scores, four groups of F8 variants were isolated, and then compared using survival curves with normalized FVIII (p < 0.0001): “long-lastingly effective” [p.(Glu739Lys), p.(Ser2030Asn), p.(Arg2178His), p.(Gln2208Glu), and T-stretch deletion in intron 13]; “moderately effective” [p.(Ser112Phe), p.(Ala219Thr), p.(Thr2105Ile), p.Phe2146Ser), and p.(Asp2150Asn)]; “moderately ineffective” [p.Ala81Asp), p.(Gln324Pro), p.(Tyr492His), p.(Arg612Cys), p.(Met701Val), p.(Val2035Asn), and p.(Arg2178Cys)]; and “frequently ineffective” [c.-219C > T, p.(Cys2040Tyr), p.(Tyr2169His), p.(Pro2319Leu), and p.(Arg2326Gln)]. Conclusion In view of our data, we propose indications for DDAVP use in PWMH based on F8 variants for minor and major invasive procedures.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
洒家完成签到 ,获得积分10
刚刚
理想夏日完成签到,获得积分10
1秒前
vn完成签到,获得积分10
2秒前
科研通AI2S应助zorn采纳,获得10
2秒前
舒服的灵安完成签到 ,获得积分10
2秒前
随心随意完成签到,获得积分10
2秒前
诸葛天完成签到 ,获得积分0
4秒前
自信安荷完成签到,获得积分10
4秒前
lemon完成签到,获得积分10
4秒前
自然怀梦完成签到,获得积分10
6秒前
刻苦的新烟完成签到 ,获得积分10
6秒前
drizzling完成签到,获得积分10
6秒前
时尚雨兰完成签到,获得积分10
10秒前
文献求助完成签到,获得积分10
10秒前
11秒前
严仕国完成签到,获得积分10
12秒前
zhenyuan完成签到,获得积分10
13秒前
今后应助科研精灵采纳,获得10
16秒前
17秒前
linddda完成签到 ,获得积分10
18秒前
18秒前
pgh.hh完成签到 ,获得积分10
18秒前
领导范儿应助zhenyuan采纳,获得10
18秒前
18秒前
郭生完成签到,获得积分10
20秒前
聪明的嘉熙完成签到,获得积分10
20秒前
Smiles发布了新的文献求助10
21秒前
Linda完成签到,获得积分10
22秒前
欣慰的书本完成签到 ,获得积分10
22秒前
Singularity应助李李采纳,获得10
24秒前
Czd完成签到 ,获得积分10
24秒前
Mito2009发布了新的文献求助10
24秒前
lighta0发布了新的文献求助10
24秒前
邵洋完成签到,获得积分20
25秒前
27秒前
Alisha完成签到,获得积分10
27秒前
赘婿应助lili采纳,获得10
28秒前
隐形傲霜完成签到 ,获得积分10
28秒前
Smiles完成签到,获得积分10
28秒前
liuchao完成签到,获得积分10
29秒前
高分求助中
Exploring Mitochondrial Autophagy Dysregulation in Osteosarcoma: Its Implications for Prognosis and Targeted Therapy 3000
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
Migration and Wellbeing: Towards a More Inclusive World 1000
Green Transition Impacts on the Economy, Society, and Environment 600
QMS18Ed2 | process management. 2nd ed 600
晶体非线性光学:带有 SNLO 示例(第二版) 570
LNG as a marine fuel—Safety and Operational Guidelines - Bunkering 560
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2951333
求助须知:如何正确求助?哪些是违规求助? 2613329
关于积分的说明 7037739
捐赠科研通 2251583
什么是DOI,文献DOI怎么找? 1194823
版权声明 590689
科研通“疑难数据库(出版商)”最低求助积分说明 584420